Financial Histogenics Corporation Announces Third Quarter 2018 Financial and Operating Results byJosh SandbergNovember 9, 2018
Financial Histogenics Corporation Announces Proposed Public Offering of Common Stock and Warrants byJosh SandbergOctober 4, 2018
Biologics Histogenics Chief Operating Officer, Stephen Kennedy Appointed to Advanced Regenerative Manufacturing Institute’s Technology Advisory Sub-Committee byJosh SandbergJuly 23, 2018
Financial Histogenics Corporation Announces First Quarter 2018 Financial and Operating Results byJosh SandbergMay 10, 2018
Biologics Histogenics Corporation Announces the Appointment of Susan Washer to Its Board of Directors byJosh SandbergApril 19, 2018
Financial Histogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2017 byJosh SandbergMarch 16, 2018
Biologics Histogenics Corporation to Present at Upcoming Investor Conferences byJosh SandbergFebruary 20, 2018
Financial Histogenics Corporation Announces Closing of Underwritten Registered Direct Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares byJosh SandbergJanuary 29, 2018
Biologics Top Stories Histogenics Corporation Announces Receipt of $10 Million Up-front Payment for Japanese NeoCart Agreement byJosh SandbergJanuary 10, 2018
Biologics Top Stories Histogenics Corporation and MEDINET Co., Ltd Enter Into Licensing Agreement for Development and Commercialization of NeoCart for the Japanese Market byJosh SandbergDecember 22, 2017
